SVB Securities analyst Joseph Schwartz lowered the firm’s price target on Fulcrum Therapeutics to $10 from $18 and keeps an Outperform rating on the shares. The firm said that while management remains confident in their ability to advance FTX-6058, the market opportunity in sickle cell disease looks like it will be smaller considering Fulcrum now needs to define the population where the potential benefit of continued treatment with FTX-6058 outweighs the potential risk.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Fulcrum Therapeutics downgraded to Neutral from Outperform at Credit Suisse
- Oppenheimer ‘not writing off’ Fulcrum Therapeutics’ 6058 ‘just yet’
- Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
